Table 4

Molecular effects of AT1 receptor antagonist on various glomerular disease models

Disease ModelAT1 Receptor Antagonist (dosage)SuppressionReference
DOCA-salt HTCandesartan (1 mg/kg/day)TGF-β1, FN, Co I, Co III, Co IV, laminin Kim et al., 1994c
SHRSPCandesartan (0.1 mg/kg/day)TGF-β1, FN, Co I, Co III, Co IV, laminin Kim et al., 1994b
Remnant kidneyLosartan (180 mg/L DW)TGF-β1 Junaid et al., 1997
Remnant kidneyCandesartan (1 mg/kg/day)Phenotypic change (α-SMA, desmin) Hamaguchi et al., 1996
Thy 1.1 GNLosartan (500 mg/L DW)TGF-β1, FN, PAI-1 Peters et al., 1998
CsA nephropathyLosartan (10 mg/kg/day)TGF-β1, PAI-1, Co I, Co IV, biglycan Shihab et al., 1997
  • HT, hypertensive rats; GN, glomerulonephritis; CsA, cyclosporin A; DW, drinking water; FN, fibronectin; Co, collagen; α-SMA, α-smooth muscle actin.